期刊文献+

Detection of serum anti-Helicobacer pylori immunoglobulin G in patients with different digestive malignant tumors 被引量:8

Detection of serum anti-Helicobacer pylori immunoglobulin G in patients with different digestive malignant tumors
下载PDF
导出
摘要 AIM: To investigate the seroprevalence of Helicobacter pylori infection in patients with different digestive malignant tumors.METHODS: Enzyme linked immunosorbent assay (ELISA) was used to detect serum anti-Helicobacter pylori IgG antibody in 374 patients with different digestive malignant tumors and 310 healthy subjects (normal control group).RESULTS: The seroprevalence of Helicobacter pylori infection was 61.50 %(230/374) and 46.77 % (145/310),respectively, in patients with digestive tumors and normal controls (P<0.05). The seroprevalence was 52.38 % (33/63),86.60 % (84/97), 83.14 % (84/101), 45.24 (19/42),51.13 % (18/35) and 44.44 % (16/36), respectively in patients with carcinomas of esophagus, stomach, duodenum,rectum, colon and liver (P<0.01). In patients with intestinal and diffuse type gastric cancers, the seroprevalence was 93.75 % (60/64) and 72.73 % (24/33), respectively (P<0.05).In patients with gastric antral and cardiac cancers, the seroprevalence was 96.43 % (54/56) and 73.17 % (30/41),respectively (P<0.05). In patients with ulcerous and proliferous type duodenal cancers, the seroprevalence of H pylori infection was 91.04 % (61/67) and 52.27 % (23/44),respectively (P<0.05). In patients with duodenal bulb and descending cancers, the seroprevalence was 94.20 % (65/69) and 45.20 % (19/42), respectively (P<0.05).CONCLUSION:Hpyloriinfection is associated with occurrence and development of gastric and duodenal carcinomas.Furthermore, it is also associated with histological type and locations of gastric and duodenal carcinomas. AIM:To investigate the seroprevalence of He/icobacterpy/ori infection in patients with different digestive malignant tumors. METHODS:Enzyme linked immunosorbent assay (ELISA) was used to detect serum anti-Helicobacter pylori IgG antibody in 374 patients with different digestive malignant tumors and 310 healthy subjects (normal control group). RESULTS:The seroprevalence of He/icobacter pylori infection was 61.50%(230/374) and 46.77% (145/310), respectively,in patients with digestive tumors and normal controls (P<0.05).The seroprevalence was 52.38% (33/63), 86.60% (84/97),83.14% (84/101),45.24 (19/42), 51.13% (18/35) and 44.44% (16/36),respectively in patients with carcinomas of esophagus,stomach,duodenum, rectum,colon and liver (P<0.01).In patients with intestinal and diffuse type gastric cancers,the seroprevalence was 93.75% (60/64) and 72.73% (24/33),respectively (P<0.05). In patients with gastric antral and cardiac cancers,the seroprevalence was 96.43% (54/56) and 73.17% (30/41), respectively (P<0.05).In patients with ulcerous and proliferous type duodenal cancers,the seroprevalence of H pylori infection was 91.04% (61/67) and 52.27% (23/44), respectively (P<0.05).In patients with duodenal bulb and descending cancers,the seroprevalence was 94.20% (65/69) and 45.20% (19/42),respectively (P<0.05). CONCLUSION:Hpyloriinfection is associated with occurrence and development of gastric and duodenal carcinomas. Furthermore,it is also associated with histological type and locations of gastric and duodenal carcinomas.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2003年第11期2501-2504,共4页 世界胃肠病学杂志(英文版)
基金 Natural Science Foundation of the Education Department of Anhui Province,China,No.2003kj111
  • 相关文献

参考文献5

二级参考文献68

  • 1Jochen Rudi,Christof Kolb,Matthias Maiwald,Ivan Zuna,Axel Von Herbay,Peter R. Galle,Wolfgang Stremmel.Serum Antibodies Against Helicobacter pylori Proteins VacA and CagA Are Associated with Increased Risk for Gastric Adenocarcinoma[J]. Digestive Diseases and Sciences . 1997 (8)
  • 2Takayoshi Matsui,Yoshizumi Matsukawa,Toshiyuki Sakai,Keiya Nakamura,Akira Aoike,Keiichi Kawai.Ammonia Inhibits Proliferation and Cell Cycle Progression at S-Phase in Human Gastric Cells[J]. Digestive Diseases and Sciences . 1997 (7)
  • 3Rachel J. Cahill MD,H Xia MD, PhD,Clive Kilgallen MB,Shona Beattie SRN,Hilary Hamilton SRN,Prof. Colm O’morain MD, MSc, FRCP.Effect of eradication ofHelicobacter pylori infection on gastric epithelial cell proliferation[J]. Digestive Diseases and Sciences . 1995 (8)
  • 4Moshe Oren.The involvement of oncogenes and tumor suppressor genes in the control of apoptosis[J]. Cancer and Metastasis Review . 1992 (2)
  • 5Watanabe T,Tada M,Nagai H,Sasaki S,Nakao M.Helicobacter Pylori infection induces gastric cancer in Monglian gerb ils. Gastroenterology . 1998
  • 6Clarke MR,Safatle-Ribeiro AV,Ribeiro U,Sakai P,Reynolds JC.bcl-2 protein expression in gastric remnant mucosa and gastric cancer 15or more years after partial gastrectomy. Modern Pathology . 1997
  • 7Farthing MJG.Helicobacter Pylori infection: an overview. British Medical Bulletin . 1998
  • 8Patchett SE,Katelaris PH,Zhang ZW,Alstead EM,Domizio P,Farthing MJG.Omithine decarboxylase activity is a marker of prem alig nancy in logn - standing Helicobacter Pytori infection. Gut . 1996
  • 9Parsonnet J,Friedman GD,Orentreich N,Vogelman H.Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut . 1997
  • 10Zhang ZW,Patchett SE,Farthing MJG. H.Pylori associated reduction in gastric cell number is associated with increased apopto sis rate, but not cell DNA synthesis rate (abstract). Gastroenterology . 1999

共引文献232

同被引文献31

引证文献8

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部